

Keytruda® (pembrolizumab) – New indication

- On June 12, 2018, <u>Merck announced</u> the FDA approval of <u>Keytruda (pembrolizumab)</u> for the
 treatment of patients with recurrent or metastatic cervical cancer with disease progression on or
 after chemotherapy whose tumors express PD-L1 (combined positive score [CPS] ≥ 1) as
 determined by an FDA-approved test.
 - This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
- Keytruda is also indicated for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instabilityhigh cancer, and gastric cancer.
- The <u>American Cancer Society</u> estimates that 13,240 new cases of cervical cancer will be diagnosed and 4,170 women will die from the disease in 2018.
- The new indication for Keytruda was based on a single cohort (cohort E) in the KEYNOTE-158 trial, involving 98 patients with recurrent or metastatic cervical cancer. The primary endpoints were objective response rate (ORR) and duration of response (DOR)
 - The ORR was 14.3% (95% CI: 7.4, 24.1).
 - The median DOR was not reached at the time of analysis, but 91% of patients achieved DOR ≥ 6 months.
- In patients with cervical cancer, the recommended dose of Keytruda is 200 mg administered as an
 intravenous infusion every 3 weeks until disease progression, unacceptable toxicity, or up to 24
 months in patients without disease progression.
 - Refer to the Keytruda drug label for dosage in other indications.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.